Opportunistic salpingectomy versus tubal ligation. A review of current strategies for ovarian cancer prevention
DOI:
https://doi.org/10.12775/JEHS.2026.88.69445Keywords
opportunistic salpingectomy, tubal ligation, ovarian cancer, serous tubal intraepithelial carcinoma, high-grade serous carcinoma, Anti-Müllerian hormone, endometriosisAbstract
Introduction and purpose. Ovarian cancer is a leading cause of gynecological mortality due to late diagnosis. Modern evidence shows that high-grade serous ovarian cancer (HGSC) often originates in the fallopian tube from serous tubal intraepithelial carcinoma (STIC) lesions. This supports opportunistic salpingectomy as a superior preventive strategy over traditional tubal ligation. This study compares both methods regarding oncological efficacy, surgical safety, and impact on ovarian reserve.
Material and method. In January 2026, a comprehensive narrative review was conducted using PubMed, Google Scholar, and JEHS archives. The analysis focused on 20 key publications (2017–2025) comparing salpingectomy and tubal ligation, focusing on HGSC prevention, Anti-Müllerian hormone (AMH) levels, and cost-effectiveness.
Results. Population data indicate that salpingectomy is more effective, reducing HGSC risk by 65–80%, compared to 24–28% for tubal ligation. Surgical analysis shows salpingectomy extends operative time by 8–15 minutes but does not increase perioperative risk. Systematic reviews show no significant decrease in AMH levels post-surgery, though a potential risk of exacerbating genitourinary syndrome was noted. Economic analyses confirm that opportunistic salpingectomy is highly cost-effective by avoiding advanced cancer treatment expenses.
Conclusions. Opportunistic salpingectomy is the gold standard for prevention in women completing their reproductive plans. It is safe, preserves hormonal function, and offers superior protection compared to tubal ligation. Preoperative counseling regarding quality of life is recommended.
References
1. Zarankiewicz N, Kosz K, Kuchnicka A, Zielińska M, Wolanin N, Ciseł B. Endometriosis and ovarian cancer - what they have in common?. J Educ Health Sport [Internet]. 2020 Aug. 17 [cited 2026 Jan. 7];10(8):230-9. Available from: https://apcz.umk.pl/JEHS/article/view/JEHS.2020.10.08.026
2. Proshchenko O, Ventskivska I. Effect of hysterectomy with opportunistic salpingectomy for uterine fibroids on the development of genitourinary syndrome and ways of its reduction. J Educ Health Sport [Internet]. 2022 Apr. 20 [cited 2026 Jan. 7];12(4):152-65. Available from: https://apcz.umk.pl/JEHS/article/view/38046
3. Proshchenko O, Govseev D. Hysterectomy with opportunistic salpingectomy during the menopausal transition as a predictor of climacteric disorders. J Educ Health Sport [Internet]. 2023 Aug. 29 [cited 2026 Mar. 1];47(1):117-24. Available from: https://apcz.umk.pl/JEHS/article/view/46543
4. Kather A, Arefian H, Schneider C, Hartmann M, Runnebaum IB. Ovarian cancer prevention through opportunistic salpingectomy during abdominal surgeries: A cost-effectiveness modeling study. PLoS Med. 2025;22(1):e1004514. Published 2025 Jan 30. doi:10.1371/journal.pmed.1004514
https://pubmed.ncbi.nlm.nih.gov/39883621/
5. Giannakeas V, Murji A, Lipscombe LL, Narod SA, Kotsopoulos J. Salpingectomy and the Risk of Ovarian Cancer in Ontario. JAMA Netw Open. 2023;6(8):e2327198. Published 2023 Aug 1. doi:10.1001/jamanetworkopen.2023.27198
https://pubmed.ncbi.nlm.nih.gov/37566421/
6. Marino S, Canela CD, Jenkins SM, Nama N. Tubal Sterilization. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 16, 2024.
https://pubmed.ncbi.nlm.nih.gov/29262077/
7. Hanley GE, Pearce CL, Talhouk A, et al. Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention. JAMA Netw Open. 2022;5(2):e2147343. Published 2022 Feb 1. doi:10.1001/jamanetworkopen.2021.47343
https://pubmed.ncbi.nlm.nih.gov/35138400/
8. Runnebaum IB, Kather A, Vorwergk J, et al. Ovarian cancer prevention by opportunistic salpingectomy is a new de facto standard in Germany. J Cancer Res Clin Oncol. 2023;149(10):6953-6966. doi:10.1007/s00432-023-04578-5
https://pubmed.ncbi.nlm.nih.gov/36847838/
9. Rufin KGA, do Valle HA, McAlpine JN, Elwood C, Hanley GE. Complications after opportunistic salpingectomy compared with tubal ligation at cesarean section: a retrospective cohort study. Fertil Steril. 2024;121(3):531-539. doi:10.1016/j.fertnstert.2023.11.031
https://pubmed.ncbi.nlm.nih.gov/38043843/
10. Subramaniam A, Einerson BD, Blanchard CT, et al. The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction. Gynecol Oncol. 2019;152(1):127-132. doi:10.1016/j.ygyno.2018.11.009
https://pubmed.ncbi.nlm.nih.gov/30477808/
11. Cerrato C, Pandolfo SD, Kraft P, Ko DSC, Mir MC. Opportunistic salpingectomy during radical cystectomy for bladder cancer: A systematic review of the literature. Asian J Urol. 2025;12(4):471-477. doi:10.1016/j.ajur.2025.03.008
https://pubmed.ncbi.nlm.nih.gov/41467203/
12. Gelderblom ME, IntHout J, Dagovic L, Hermens RPMG, Piek JMJ, de Hullu JA. The effect of opportunistic salpingectomy for primary prevention of ovarian cancer on ovarian reserve: a systematic review and meta-analysis. Maturitas. 2022;166:21-34. doi:10.1016/j.maturitas.2022.08.002
https://pubmed.ncbi.nlm.nih.gov/36030627/
13. van Lieshout LAM, Steenbeek MP, De Hullu JA, et al. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. Cochrane Database Syst Rev. 2019;8(8):CD012858. Published 2019 Aug 28. doi:10.1002/14651858.CD012858.pub2
https://pubmed.ncbi.nlm.nih.gov/31456223/
14. Venkatesh KK, Clark LH, Stamilio DM. Cost-effectiveness of opportunistic salpingectomy vs tubal ligation at the time of cesarean delivery. Am J Obstet Gynecol. 2019;220(1):106.e1-106.e10. doi:10.1016/j.ajog.2018.08.032
https://pubmed.ncbi.nlm.nih.gov/30170036/
15. Kader T, Lin JR, Hug CB, et al. Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma. Cancer Discov. 2025;15(6):1180-1202. doi:10.1158/2159-8290.CD-24-1366
https://pubmed.ncbi.nlm.nih.gov/39704522/
16. Schneider S, Heikaus S, Harter P, et al. Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases. Int J Gynecol Cancer. 2017;27(3):444-451. doi:10.1097/IGC.0000000000000920
https://pubmed.ncbi.nlm.nih.gov/28187099/
17. Shih IM, Wang Y, Wang TL. The Origin of Ovarian Cancer Species and Precancerous Landscape. Am J Pathol. 2021;191(1):26-39. doi:10.1016/j.ajpath.2020.09.006
https://pubmed.ncbi.nlm.nih.gov/33011111/
18. Pölcher M, Wimberger P, Meinhold-Heerlein I, et al. Intergroup statement: opportunistic salpingectomy-molecular pathology, clinical outcomes and implications for practice (German Ovarian Cancer Commission, the North-Eastern German Society of Gynecologic Oncology (NOGGO), AGO Austria and AGO Swiss). Arch Gynecol Obstet. 2025;311(5):1451-1459. doi:10.1007/s00404-025-07974-z
https://pubmed.ncbi.nlm.nih.gov/40172609/
19. ACOG Committee Opinion No. 774: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention. Obstet Gynecol. 2019;133(4):e279-e284. doi:10.1097/AOG.0000000000003164
https://pubmed.ncbi.nlm.nih.gov/30913199/
20. Kyo S, Ishikawa N, Nakamura K, Nakayama K. The fallopian tube as origin of ovarian cancer: Change of diagnostic and preventive strategies. Cancer Med. 2020;9(2):421-431. doi:10.1002/cam4.2725
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Aleksandra Anna Miciak, Aleksandra Karolina Węglarz, Patrycja Anna Borowiecka, Jagoda Anna Adamarczuk, Jacek Głuski, Nina Urantówka, Aleksandra Wojtera, Marta Omiecińska, Karina Barbara Kaszowska, Tomasz Piotr Dąbrowski, Karolina Kaczmarz-Chojnacka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 35
Number of citations: 0
